Ami Knoefler
Contatto Relazioni con gli Investitori presso ADAGENE INC.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Peizhi Luo | M | 59 | 13 anni | |
| Yiu Leung Cheung | M | 64 | 3 anni | |
| Mervyn Turner | M | 77 | 1 anni | |
| Cuong Viet Do | M | 58 | 2 anni | |
| Fang Yong Du | M | 55 | 12 anni | |
| Min Li | M | 62 | 3 anni | |
| Man Kin Tam | M | 47 | 5 anni | |
| Songmao Zheng | M | - | 3 anni | |
| Gui Zhong Liu | M | 54 | 9 anni | |
| Ling Zhou | F | - | 5 anni | |
| Dana Hu-Lowe | M | - | 3 anni | |
| Alexander Goergen | M | 38 | 7 anni | |
| Charles R. Cantor | M | 81 |
Boston University
| 32 anni |
| Qing Hai Zhao | M | 64 | 4 anni | |
| JC Xu | M | 60 | 4 anni | |
| Yumeng Wang | F | 33 | 1 anni | |
| Xiao Hong She | F | 58 | 13 anni | |
| Yan Li | F | 50 | 13 anni | |
| Jiping Zha | M | - | 3 anni | |
| Chunfang Gu | F | - | 7 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Francis Sarena | M | 53 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 anni |
| Bradford Goodwin | M | 69 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 anni |
| Herbert Cross | M | 52 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | - |
| Faheem Hasnain | M | 65 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
| Cynthia Shumate | F | 62 | 4 anni | |
| Yu Wen Liu | F | - | 1 anni | |
| Katherine O'Neil | F | - |
Boston University
| 5 anni |
| Minalkumar Patel | M | 52 |
Boston University
| 7 anni |
| James Markarian | M | 57 |
Boston University
| 5 anni |
| Francis Han Joe Tjia | M | 59 |
Boston University
| 2 anni |
| Peter H. Calcott | M | 75 | - | |
| Reza Dehkordy Hamid Behnam | M | - |
Boston University
| 5 anni |
| Imad Osama Abdul Rahim Asfour | M | 57 |
Boston University
| 3 anni |
| Cary L. Queen | M | 73 | 20 anni | |
| Adam David Seitchik | M | - |
Boston University
| 4 anni |
| Andrew M. Jacobson | M | - |
Boston University
| 3 anni |
| Mitchell A. Garrison | M | - |
Boston University
| 8 anni |
| Mark McCamish | M | 72 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
| Luis R. Cortez | M | - |
Boston University
| 5 anni |
| Ran Zhang | M | 56 |
Boston University
| 4 anni |
| Andrew Guggenhime | M | 55 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 anni |
| Ramdas Rao | M | 59 |
Boston University
| 10 anni |
| Suzanne Hendrix | M | - |
Boston University
| 4 anni |
| Kartini Syahrir | M | 71 |
Boston University
| 4 anni |
| Jon Saxe | M | 88 | 19 anni | |
| Lisa J. Lee-Hwong | M | - |
Boston University
| 8 anni |
| Mark McDade | M | 69 | 5 anni | |
| Mohamed Sharara | M | - |
Boston University
| 5 anni |
| Timothy E. Hawkins | M | - |
Boston University
| 9 anni |
| Reem Haitham Jamil Goussous | F | 52 |
Boston University
| 6 anni |
| Petrus Halim | M | 54 |
Boston University
| 5 anni |
| James T. McDonald | M | - |
Boston University
| 1 anni |
| Kathryn C. Kling | F | - |
Boston University
| 3 anni |
| Lan Xie | F | 51 |
Boston University
| 4 anni |
| André de Baubigny | M | - |
Boston University
| 3 anni |
| Jeffrey Beck | M | 61 |
Boston University
| 2 anni |
| Bill Mountford | M | - |
Boston University
| 4 anni |
| Louis E. Lataif | M | 84 |
Boston University
| 19 anni |
| Charles C. Herlocher | M | 60 |
Boston University
| - |
| Carl Mower | M | - |
Boston University
| 1 anni |
| Hadley Wilkins | F | - |
Boston University
| 4 anni |
| Urvashi Rangan | M | - |
Boston University
| 4 anni |
| Joshua Siegel | M | - |
Boston University
| 4 anni |
| Anthony A. Burdin | M | 50 |
Boston University
| 4 anni |
| Anil Chitkara | M | 55 |
Boston University
| 4 anni |
| Chong Fai Wong | M | 53 |
Boston University
| 4 anni |
| Zartosht Farahmand | M | - |
Boston University
| 2 anni |
| Davis Jiang | M | - |
Boston University
| 4 anni |
| James P. Galligan | M | - |
Boston University
| 4 anni |
| Tom A. L. Pereira | M | - |
Boston University
| 4 anni |
| Ann Peters | F | - |
Boston University
| 4 anni |
| Daniel Taub | M | 53 |
Boston University
| 4 anni |
| David Conn | M | 56 |
Boston University
| 4 anni |
| Scott Storrer | M | 56 |
Boston University
| 2 anni |
| Jeffrey DiModica | M | 56 |
Boston University
| 4 anni |
| Gregory Nicastro | M | - |
Boston University
| 1 anni |
| Matt Eagan | M | - |
Boston University
| 4 anni |
| Nevin Chitkara | M | - |
Boston University
| 4 anni |
| Mark Notkin | M | - |
Boston University
| 2 anni |
| Dan Scherman | M | 62 |
Boston University
| 3 anni |
| Steven A. Greenberg | M | 57 |
Boston University
| 4 anni |
| Dan Henderson | M | - |
Boston University
| 4 anni |
| Susan Simi | F | - |
Boston University
| 6 anni |
| David Kelson | M | - |
Boston University
| 4 anni |
| Bryan Biniak | M | 55 |
Boston University
| 4 anni |
| Bruce W. Minsky | M | 60 |
Boston University
| 3 anni |
| Ralph J. Folz | M | - |
Boston University
| 1 anni |
| Raul R. Rai | M | - |
Boston University
| 4 anni |
| Gregory Baldwin | M | - |
Boston University
| - |
| Steven D. Girouard | M | - |
Boston University
| 4 anni |
| Jon Glass | M | - |
Boston University
| 3 anni |
| Stephen Feldschuh | M | 88 |
Boston University
| 4 anni |
| John Tripp | M | 62 |
Boston University
| 2 anni |
| John M. Grady | M | - |
Boston University
| 6 anni |
| Brooks E. West | M | 54 |
Boston University
| 4 anni |
| R. Robert Nagel | M | - |
Boston University
| 9 anni |
| Timothy E. Askew | M | - |
Boston University
| 2 anni |
| Richard P. Milgram | M | - |
Boston University
| 4 anni |
| Douglas B. Grane | M | - |
Boston University
| 4 anni |
| Astini Bernawati Oudang | F | 53 |
Boston University
| 4 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 80 | 80.00% |
| Cina | 20 | 20.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Ami Knoefler
- Contatti personali
